Development of a cell line-based in vitro assay for assessment of Diphtheria, Tetanus and acellular Pertussis (DTaP)-induced inflammasome activation

• Published in: Vaccine 2022-09, Vol.40 (38), p.5601-5607
• Main Authors: Vandebriel, Rob J., Stalpers, Coen A.L., Vermeulen, Jolanda P., Remkes, Mariska, Schmelter, Marit, Broere, Femke, Hoefnagel, Marcel H.N.
• Format: Article
• Language: English
• Subjects: Adjuvant; Adjuvants; Aluminium hydroxide; Aluminium phosphate; Aluminum; Aluminum phosphate; Antigens; Apoptosis; Assaying; Biological activity; Cell viability; Consistency approach; Diphtheria; Evaluation; Experiments; Freeze thaw cycles; Freeze-thawing; IL-1β; Immune response; Inflammasome; Inflammasomes; NLRP3; Pertussis; Phosphorylation; Quality management; Salts; Software; Tetanus; Vaccines; Whooping cough
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2022.08.022

•The consistency approach is an avenue for vaccine batch release without animal testing.•In vitro testing of adjuvant biological activity contributes to animal-free potency testing of vaccines.•The aluminium-based vaccines and adjuvants tested showed in vitro NLRP3 inflammasome activation.•Benchmark dose modelling showed the activation to be due to the adjuvant only.•In vitro inflammasome activation may be used to measure adjuvant biological activity. Safety and potency assessment for batch release testing of established vaccines still relies partly on animal tests. An important avenue to move to batch release without animal testing is the consistency approach. This approach is based on thorough characterization of the vaccine to identify critical quality attributes that inform the use of a comprehensive set of non-animal tests to release the vaccine, together with the principle that the quality of subsequent batches follows from their consistent production. Many vaccine antigens are by themselves not able to induce a protective immune response. The antigens are therefore administered together with adjuvant, most often by adsorption to aluminium salts. Adjuvant function is an important component of vaccine potency, and an important quality attribute of the final product. Aluminium adjuvants are capable of inducing NLRP3 inflammasome activation. The aim of this study was to develop and evaluate an in vitro assay for NLRP3 inflammasome activation by aluminium-adjuvanted vaccines. We evaluated the effects of Diphtheria-Tetanus-acellular Pertussis combination vaccines from two manufacturers and their respective adjuvants, aluminium phosphate (AP) and aluminium hydroxide (AH), in an in vitro assay for NLRP3 inflammasome activation. All vaccines and adjuvants tested showed a dose-dependent increase in IL-1β production and a concomitant decrease in cell viability, suggesting NLRP3 inflammasome activation. The results were analysed by benchmark dose modelling, showing a similar 50% effective dose (ED50) for the two vaccine batches and corresponding adjuvant of manufacturer A (AP), and a similar ED50 for the two vaccine batches and corresponding adjuvant of manufacturer B (AH). This suggests that NLRP3 inflammasome activation is determined by the adjuvant only. Repeated freeze-thaw cycles reduced the adjuvant biological activity of AH, but not AP. Inflammasome activation may be used to measure adjuvant biological activity as an important quality attribute for contr